scholarly journals Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b

2014 ◽  
Vol 66 (1) ◽  
pp. 193-201 ◽  
Author(s):  
Snezana Jovanovic-Cupic ◽  
S. Glisic ◽  
M. Stanojevic ◽  
N. Vasiljevic ◽  
T. Bojic-Milinovic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Therapy Response ◽  
Pegylated Interferon ◽  
Response To Therapy ◽  
Genotype 1B

Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patient?s likelihood of achieving sustained viral response.

scholarly journals Hepatitis C Therapy – Related Haematological Side Effects are Associated with Treatment Outcome / Hematološka Neželjena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja

2016 ◽  
Vol 17 (1) ◽  
pp. 9-14
Author(s):  
Vuk R. Vukovic ◽  
Dejan Baskic ◽  
Zeljko Mijailovic ◽  
Predrag Djurdjevic
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Side Effects ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Pegylated Interferon ◽  
Response To Therapy ◽  
Pegylated Interferon Alpha

Abstract Treatment of patients suffering from chronic hepatitis C with standard pegylated interferon alpha 2a plus ribavirin has limited efficacy. Therapy outcome is dependent on several factors of both the host and virus, including age, sex, stage of fibrosis, viral genotype, viral load, and occurrence of haematological adverse events during chronic hepatitis C treatment. The aim of this study was to determine the relationship between the viral and host factors and the haematological side effects of therapy with sustained virological response. Fifty-four patients were treated with combined pegylated interferon alpha 2a plus ribavirin therapy. Hepatitis C virus genotyping, viral load, histopathological liver changes and biochemical parameters were evaluated for each patient before beginning treatment. Each patient’s blood count was analysed during each clinical visit. Sustained virological response was achieved in 75,9% of patients. Baseline AST and ALT levels were significantly higher in patients with a poor response to therapy (p<0,05). Other clinical and laboratory parameters did not reach statistical significance. Both responders and non-responders developed anaemia. A decrease in thrombocytes, neutrophils and white blood cells was significantly associated with a sustained response to therapy (p<0,05, p<0,05 and p<0,001, respectively). Sustained virological response was associated with lower baseline AST and ALT values and thrombocytopenia, leucopenia and neutropenia at the end of the treatment. All treated patients developed anaemia.

scholarly journals Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load

2009 ◽  
Vol 3 (3) ◽  
pp. 372-376 ◽  
Author(s):  
Kenji Ando ◽  
Soo Ryang Kim ◽  
Susumu Imoto ◽  
Taisuke Nakajima ◽  
Keiji Mita ◽  
...  
Keyword(s):  
Acute Pancreatitis ◽  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
High Viral Load ◽  
Genotype 1B

scholarly journals Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral Load

2013 ◽  
Vol 31 (5-6) ◽  
pp. 426-433
Author(s):  
Soo Ryang Kim ◽  
Ahmed El-Shamy ◽  
Susumu Imoto ◽  
Ke Ih Kim ◽  
Kayo Sugimoto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
High Viral Load ◽  
Prediction Of Response

scholarly journals Role of host and viral factors and genetic variation of IL28B on therapy outcome in patients with chronic hepatitis C genotype 1b from Serbia

2019 ◽  
Vol 3 (1) ◽  
pp. 36 ◽  
Author(s):  
Snežana Jovanović-Ćupić ◽  
Nina Petrovic ◽  
Milena Krajnović ◽  
Maja Bundalo ◽  
Nikola Kokanov ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Response To Therapy ◽  
Therapy Outcome ◽  
Taqman Assay ◽  
Genotype 1B ◽  
Route Of Transmission

In hepatitis C virus (HCV) infection viral and host factors can influence therapy outcome to pegylated interferon/ribavirin (PEG-IFN/RBV) and progression of liver fibrosis. Although novel direct-acting antivirals (DAAs) show newly successful treatment of hepatitis C infection, the majority of patients are unable to access this therapy because of cost and so remain untreated. Also, the efficacy of treatment with new therapy may be affected by the presence of resistance-associated substitutions (RASs). This study was designed to describe associations between baseline host and viral factors, progression of liver fibrosis and response to therapy with pegylated interferon/ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C (HCV) genotype 1b. We analyzed pre-treatment of 100 patients with chronic hepatitis C genotype 1b and related it to outcome of therapy. TaqMan assay was used to determine SNP rs12979860 in all patients. In our study there was significant correlation between age and response to therapy. Also, we found associations between a known route of transmission and age, gender, stage of liver fibrosis and therapy outcome. With respect to SNP rs12979860, the frequency of the CC genotype in the group with a sustained virologic response (SVR) was significantly higher than in the group of non-responders (NR). In contrast, there was no correlation between IL28B polymorphism and progression of liver fibrosis.

scholarly journals Pegylated interferon α-2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b

Kanzo ◽  
2008 ◽  
Vol 49 (4) ◽  
pp. 145-152
Author(s):  
Soo Ryang Kim ◽  
Susumu Imoto ◽  
Shuichi Fuki ◽  
Ke Ih Kim ◽  
Miyuki Taniguchi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Elderly Patients ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
High Viral Load ◽  
Interferon Α ◽  
Hcv Genotype

scholarly journals IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C

2011 ◽  
Vol 33 (10) ◽  
pp. 1162-1172 ◽  
Author(s):  
G. Fattovich ◽  
L. Covolo ◽  
S. Bibert ◽  
G. Askarieh ◽  
M. Lagging ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Response To Therapy
Sign in / Sign up

Export Citation Format

Share Document